Effect of Graves' disease on the prognosis of differentiated thyroid carcinoma: a meta-analysis

被引:12
作者
Song, Yang [1 ,2 ]
Fu, Lijun [1 ]
Wang, Pu [3 ]
Sun, Ning [1 ]
Qiu, Xinguang [1 ]
Li, Jianhua [1 ]
Zheng, Shouhua [1 ]
Ren, Shuwei [2 ]
Ding, Xiaochong [2 ]
Li, Liwen [1 ]
Du, Junwei [1 ]
Wang, Chenyi [1 ]
Jiao, Zan [1 ]
Zhao, Wending [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Thyroid Surg, Construct Rd 1, Zhengzhou, Henan, Peoples R China
[2] Xinyang Cental Hosp, Dept Oncol Surg, Siyi Rd 1, Xinyang, Peoples R China
[3] Peking Univ, Dept Plast & Reconstruct Surg, Hosp 3, Huayuanbei St 49, Beijing, Peoples R China
关键词
Graves' disease; Differentiated thyroid carcinoma; Recurrence; Mortality; CANCER; MANAGEMENT; EXPERIENCE;
D O I
10.1007/s12020-019-02111-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose Several studies have reported different findings on the prognosis of differentiated thyroid carcinoma combined with Graves' disease. To assess the effect of Graves' disease on differentiated thyroid carcinoma, a meta-analysis was undertaken. Methods PubMed, OVID and the Cochrane Library were systematically searched for trials published prior to Oct. 2018. Studies containing data on the outcomes of Graves' disease with differentiated thyroid carcinoma were included. Summary estimates of the prevalence of recurrence/disease progression/persistence and mortality as well as odds ratios and weighted mean differences were calculated with a random-effects model. Results Of the 916 related articles found, 13 fulfilled the inclusion criteria. The recurrence/disease progression/persistent rate was not significantly different between the Graves' disease group and the non-Graves' disease group (P = 0.86). However, the analysis of three studies with K-M curves or HRs showed that there was a significant difference between the two groups (P = 0.04). Subgroup analysis showed that the contradictory results could be due to the location/race assessed in the studies. Graves' disease almost acted as a risk factor (OR = 1.77, 95%C.I. = 0.99-3.16) for differentiated thyroid carcinoma in European studies. When heterogeneous studies were excluded, the analyses show that GD was a risk factor for recurrence/disease progression/persistence (P = 0.03, OR = 1.75, 95%C.I. = 1.04-2.95). The overall mortality rate was significantly higher in the Graves' disease group than in the non-Graves' disease group (P = 0.02, OR = 2.93, 95%C.I. = 1.17-7.37). Conclusions Graves' disease acts as a risk factor for the prognosis of differentiated thyroid carcinoma. The recurrence/disease progression/persistent rate may be affected by TSAbs in a specific location/race and with a genetic immunization background. However, the histotypes and subtypes may play an important role in mortality rate.
引用
收藏
页码:516 / 525
页数:10
相关论文
共 31 条
[1]   INCREASED AGGRESSIVENESS OF THYROID-CANCER IN PATIENTS WITH GRAVES-DISEASE [J].
BELFIORE, A ;
GAROFALO, MR ;
GIUFFRIDA, D ;
RUNELLO, F ;
FILETTI, S ;
FIUMARA, A ;
IPPOLITO, O ;
VIGNERI, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (04) :830-835
[2]   Clinical diagnosis of Graves' or non-Graves' hyperthyroidism compared to TSH receptor antibody test [J].
Bell, Lauren ;
Hunter, Ann Louise ;
Kyriacou, Angelos ;
Mukherjee, Annice ;
Syed, Akheel A. .
ENDOCRINE CONNECTIONS, 2018, 7 (04) :504-510
[3]   Higher Incidence of Tall Cell Variant of Papillary Thyroid Carcinoma in Graves' Disease [J].
Boutzios, Georgios ;
Vasileiadis, Ioannis ;
Zapanti, Evangelia ;
Charitoudis, Georgios ;
Karakostas, Efthimios ;
Ieromonachou, Panagiotis ;
Karatzas, Theodore .
THYROID, 2014, 24 (02) :347-354
[4]   Graves' disease [J].
Brent, Gregory A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) :2594-2605
[5]  
CADY B, 1979, CANCER, V43, P810, DOI 10.1002/1097-0142(197903)43:3<810::AID-CNCR2820430306>3.0.CO
[6]  
2-B
[7]   Outcome of patients surgically treated for various forms of hyperthyroidism with differentiated thyroid cancer: Experience at an endocrine center in Italy [J].
Cappelli, C ;
Braga, M ;
Martino, ED ;
Castellano, M ;
Gandossi, E ;
Agosti, B ;
Cumetti, D ;
Pirola, I ;
Mattanza, C ;
Cherubini, L ;
Rosei, EA .
SURGERY TODAY, 2006, 36 (02) :125-130
[8]   Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance [J].
Gee, Julia M. W. ;
Nicholson, Robert I. ;
Barrow, Denise ;
Dutkowski, Carol M. ;
Goddard, Lindy ;
Jordan, Nicola J. ;
McClelland, Richard A. ;
Knowlden, Janice M. ;
Francies, Hayley E. ;
Hiscox, Stephen E. ;
Hutcheson, Iain R. .
HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION, 2011, 5 (02) :67-77
[9]   Incidental versus non-incidental thyroid carcinoma: Clinical presentation, surgical management and prognosis [J].
Gonzalez-Sanchez-Migallon, Elena ;
Flores-Pastor, Benito ;
Victoria Perez-Guarinos, Carmen ;
Miguel-Perello, Joana ;
Chaves-Benito, Asuncion ;
Illan-Gomez, Fatima ;
Carrillo-Alcaraz, Andres ;
Luis Aguayo-Albasini, Jose .
ENDOCRINOLOGIA Y NUTRICION, 2016, 63 (09) :475-481
[10]   2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J].
Haugen, Bryan R. ;
Alexander, Erik K. ;
Bible, Keith C. ;
Doherty, Gerard M. ;
Mandel, Susan J. ;
Nikiforov, Yuri E. ;
Pacini, Furio ;
Randolph, Gregory W. ;
Sawka, Anna M. ;
Schlumberger, Martin ;
Schuff, Kathryn G. ;
Sherman, Steven I. ;
Sosa, Julie Ann ;
Steward, David L. ;
Tuttle, R. Michael ;
Wartofsky, Leonard .
THYROID, 2016, 26 (01) :1-133